PAG
ATOS icon

Private Advisor Group’s Atossa Therapeutics ATOS Stock Holding History

Private Advisor Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-668
Closed -$8K – 1687
2022
Q3 		$8K Sell
668
-107
-14% -$1.55K ﹤0.01% 1894
2022
Q2 		$13K Buy
775
+17
+2% +$268 ﹤0.01% 2083
2022
Q1 		$14K Buy
758
+11
+1% +$223 ﹤0.01% 2076
2021
Q4 		$18K Hold
747
– – ﹤0.01% 2111
2021
Q3 		$37K Buy
+747
New +$43.5K ﹤0.01% 1989

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Private Advisor Group's ATOS Position: Q4 2022 in Review

Private Advisor Group sold out of Atossa Therapeutics (ATOS) in Q4 2022, closing a stake of 668 shares — an estimated $8K sold.

Private Advisor Group first reported a position in ATOS in Q3 2021 and held it in 5 quarters. The position peaked at $37K in Q3 2021. 51 funds tracked by Wall St. Rank hold ATOS as of Q4 2022.

  • Private Advisor Group reported no remaining Atossa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Private Advisor Group sold 668 Atossa Therapeutics shares in Q4 2022, an estimated $8K.
  • Private Advisor Group first reported a position in Atossa Therapeutics in Q3 2021 and held it in 5 quarters.
  • Private Advisor Group's Atossa Therapeutics position peaked at $37K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2022.

Based on Private Advisor Group's 13F filing for Q4 2022, filed 18 Jan 2023.